Notable Runner: Is Selling Stock Like Aquinox Pharmaceuticals Inc After Such Decline Winning Strategy?

Notable Runner: Is Selling Stock Like Aquinox Pharmaceuticals Inc After Such Decline Winning Strategy?

The stock of Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) is a huge mover today! The stock decreased 1.91% or $0.26 during the last trading session, hitting $13.36. About 368,214 shares traded hands. Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) has risen 50.28% since February 29, 2016 and is uptrending. It has outperformed by 39.86% the S&P500.
The move comes after 7 months negative chart setup for the $286.10 million company. It was reported on Oct, 1 by Barchart.com. We have $12.02 PT which if reached, will make NASDAQ:AQXP worth $28.61M less.

Analysts await Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) to report earnings on November, 8. They expect $-0.62 EPS, down 44.19% or $0.19 from last year’s $-0.43 per share. After $-0.63 actual EPS reported by Aquinox Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -1.59% EPS growth.

Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) Ratings Coverage

Out of 5 analysts covering Aquinox Pharma (NASDAQ:AQXP), 3 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 60% are positive. Aquinox Pharma has been the topic of 6 analyst reports since September 11, 2015 according to StockzIntelligence Inc. The company was maintained on Friday, August 5 by Jefferies. Jefferies maintained it with “Hold” rating and $9 target price in Tuesday, March 15 report. Leerink Swann initiated the shares of AQXP in a report on Monday, September 21 with “Outperform” rating. Needham initiated the shares of AQXP in a report on Friday, October 23 with “Buy” rating. Canaccord Genuity maintained the shares of AQXP in a report on Friday, September 11 with “Hold” rating. The rating was initiated by Guggenheim with “Buy” on Tuesday, October 6.

According to Zacks Investment Research, “Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada.”

More important recent Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) news were published by: Marketwatch.com which released: “Aquinox Pharmaceuticals Inc.” on March 10, 2014, also Marketwatch.com published article titled: “Aquinox Pharmaceuticals stock skyrockets 450%”, Marketwatch.com published: “Aquinox stock rockets 2000%, Twitter goes nuts” on August 10, 2015. More interesting news about Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) was released by: Seekingalpha.com and their article: “Updating My Thesis On Aquinox After The Equity Raise” with publication date: September 28, 2016.

AQXP Company Profile

Aquinox Pharmaceuticals, Inc., incorporated on May 25, 2007, is a clinical-stage pharmaceutical firm discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Firm operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway. The Company’s product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Firm is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. It has completed and reported results from its Leadership trial, which is a multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial investigating the ability of over 200 milligrams oral, once daily AQX-1125 to reduce pain and urinary symptoms in female patients with IC/BPS.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment